Ensemble Therapeutics Corp.
| File:EnsembleTherapeuticsLogo.png | |
| private | |
| ISIN | 🆔 |
| Industry | Health care Biotechnology |
| Fate | permanently closed |
| Founded 📆 | 2004 |
| Founder 👔 | David R. Liu |
| Headquarters 🏙️ | , , United States |
Area served 🗺️ | |
Key people | Michael D. Taylor Nick K. Terrett |
| Products 📟 | Ensemblins™ (under development) |
| Members | |
Number of employees | |
| 🌐 Website | ensembletherapeutics.com |
| 📇 Address | |
| 📞 telephone | |
Ensemble Therapeutics Corporation was a privately held pharmaceutical and biotechnology company located in Cambridge, Massachusetts. Founded in 2004 by Harvard chemist David R. Liu, the company attempted to develop and bring to market synthetic macrocycle drugs, that is, compounds with a characteristic macrocyclic ring structure, under the trademark Ensemblins. If successful, Ensemblins would be a new class of drugs, with some properties between small molecules and biologics. An orally active antagonist to Interleukin 17 has shown activity in animal models.[1]
Management[edit]
John Ripple became chief executive officer in 2013. Nick K. Terrett has been the chief scientific officer since 2006. Founder David R. Liu chairs the scientific advisory board.[2]
Ownership[edit]
Ensemble is principally owned by Flagship Ventures, a venture capital firm whose founder, Noubar Afeyan, chairs its board.[3] Other investors include ARCH Venture Partners, CMEA, Harris & Harris, Kisco Ltd., and Boston University. As of 2012, Ensemble has raised $38.5 million of equity financing.[1]
Partnerships[edit]
Ensemble has entered into partnerships that allow its macrocycle libraries to be accessed for the purpose of affinity screening drug discovery against targets that are otherwise difficult to address. Partner firms include Novartis, Alexion, Boehringer Ingelheim, Genentech, Bristol-Myers Squibb, and Pfizer.[4][5]
Closure[edit]
Ensemble Therapeutics has quietly ceased to exist in November 2017.[6]
References[edit]
- ↑ 1.0 1.1 "Ensemble Therapeutics Fact Sheet" (November 28, 2012)
- ↑ BloombergBusinessweek, "Company Overview of Ensemble Therapeutics Corporation"
- ↑ Flagship Ventures, "Ensemble Therapeutics Corporation"
- ↑ BusinessWire, "Ensemble Therapeutics Presents Data Demonstrating Unique Properties of Synthetic Macrocycles" (February 13, 2013)
- ↑ BusinessWire, "Ensemble Therapeutics Extends Macrocycle Drug Discovery Alliance with Bristol-Myers Squibb"(January 5, 2012)
- ↑ https://www.biospace.com/article/unique-cambridge-s-ensemble-therapeutics-quietly-shuts-down-after-13-years/
 | This article about a medical, pharmaceutical or biotechnological corporation or company is a stub. You can help EverybodyWiki by expanding it. |
This article "Ensemble Therapeutics" is from Wikipedia. The list of its authors can be seen in its historical. Articles copied from Draft Namespace on Wikipedia could be seen on the Draft Namespace of Wikipedia and not main one.
- 2004 establishments in Massachusetts
- Biotechnology companies of the United States
- Companies based in Cambridge, Massachusetts
- Biotechnology companies established in 2004
- Pharmaceutical companies of the United States
- Privately held companies based in Massachusetts
- Pharmaceutical companies established in 2004
- Health care companies based in Massachusetts
- Medical company stubs
